# Travere Therapeutics (TVTX): value investors who own it

1 value investor held Travere Therapeutics in their Q3 2026 13F, led by Polen Capital Management.

## 13F holders

| Manager | Portfolio | Value | Change | Quarters held |
| --- | --- | --- | --- | --- |
| Polen Capital Management | 0.0% | $1.9m | New | 1 |

## Directors buying and selling (Form 4, last 12 months)

| Date | Who | Role | Bought or sold | Shares | Value |
| --- | --- | --- | --- | --- | --- |
| 2026-10-15 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Sold | 128065 | $6.8m |
| 2026-10-15 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Sold | 78400 | $4.3m |
| 2026-10-15 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Sold | 37270 | $2.0m |
| 2026-09-17 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Sold | 101691 | $6.6m |
| 2026-09-17 | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | Sold | 8282 | $539k |
| 2026-09-17 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Sold | 6802 | $442k |
| 2026-09-16 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Sold | 99716 | $6.3m |
| 2026-09-16 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Sold | 96125 | $6.1m |
| 2026-09-16 | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | Sold | 93604 | $5.9m |
| 2026-09-16 | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | Sold | 79113 | $5.0m |
| 2026-09-16 | ROTE WILLIAM E. | Chief Research Officer | Sold | 65104 | $4.1m |
| 2026-09-16 | ROTE WILLIAM E. | Chief Research Officer | Sold | 47746 | $3.0m |
| 2026-09-15 | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | Sold | 71938 | $4.5m |
| 2026-09-15 | ROTE WILLIAM E. | Chief Research Officer | Sold | 63907 | $4.0m |
| 2026-09-15 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Sold | 63498 | $3.9m |
| 2026-09-15 | ROTE WILLIAM E. | Chief Research Officer | Sold | 29021 | $1.8m |
| 2026-09-15 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Sold | 28796 | $1.8m |
| 2026-09-15 | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | Sold | 27421 | $1.7m |
| 2026-09-15 | Cline Christopher R. | CHIEF FINANCIAL OFFICER | Sold | 27473 | $1.7m |
| 2026-09-15 | Inrig Jula | EVP, Head of R&D & CMO | Sold | 25390 | $1.6m |

Source: SEC filings, via moatshark (https://www.moatshark.com/s/tvtx). Values traded and returns are estimates. Not investment advice. Built 2026-10-21.